The agreement provides pelareorep access to a marketed PD-1 inhibitor without upfront cost, but the study is early-stage (Phase 2, single indication) and results are at least 12-18 months away. Monitor for enrollment updates and interim data; the deal does not change Oncolytics' near-term cash runway or revenue outlook.
Drugs in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.3700entry
- T+1 · 20h ago −8.14%α −6.22% · $0.3399
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech entered a clinical supply agreement with Coherus Oncology to evaluate its oncolytic virus pelareorep in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to start in Q1 2027 at a U.S. cancer center, targeting patients who have progressed on first-line chemo-immunotherapy. This is a non-dilutive supply deal with no upfront payment or milestone disclosed, providing pelareorep access to a marketed checkpoint inhibitor for a new indication with no approved second-line therapy.
Key Facts
- Clinical supply agreement with Coherus Oncology for LOQTORZI (toripalimab-tpzi) in combination with pelareorep
- Study targets second-line squamous cell anal carcinoma (SCAC) patients who progressed on first-line chemo-immunotherapy
- No approved therapy exists for second-line SCAC
- Study expected to begin Q1 2027 at a U.S. cancer center (to be named)
- Coherus provides LOQTORZI; no financial terms (upfront, milestones, or royalties) disclosed
- Pelareorep has Fast Track designation from FDA for colorectal, anal, and pancreatic cancer
Financial Impact
No financial terms disclosed; non-dilutive supply agreement with no stated upfront or milestone payments
Risk Factors
- Clinical trial may fail to show efficacy or safety, delaying or ending the SCAC program
- No financial terms disclosed; deal does not provide funding for Oncolytics' operations
- Study start is contingent on partnering with a U.S. cancer center; timeline may slip
- SCAC is a small indication; even positive data may not materially impact valuation without broader HPV-associated cancer expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402874 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Viewing Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers